- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Consistency of Product Quality for SB5, an Adalimumab Biosimilar ; volume:37 ; number:2 ; day:31 ; month:1 ; year:2023 ; pages:271-277 ; date:3.2023
BioDrugs ; 37, Heft 2 (31.1.2023), 271-277, 3.2023
- Urheber
-
Lee, JongAh Joanne
Lee, Nayoung
Seo, Young Jun
Kim, Ilkoo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-023-00581-x
- URN
-
urn:nbn:de:101:1-2023101922144165446249
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, JongAh Joanne
- Lee, Nayoung
- Seo, Young Jun
- Kim, Ilkoo
- SpringerLink (Online service)
Ähnliche Objekte (12)
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab